The Toxicologist - Society of Toxicology

More documents

Recommendations

Info

KEY WORD INDEX Keyword Index (Continued) oxidative stress ........ 161, 206, 324, 338, 410, 460, 461, 462, 697, 741, 757, 948, 1059, 1099, 1270, 1271, 1276, 1277, 1283, 1284, 1291, 1298, 1301, 1308, 1333, 1376, 1435, 1461, 1462, 1465, 1491, 1510, 1665, 1672, 1716, 1764, 1786, 1788, 1789, 2040, 2063, 2068, 2124, 2128, 2166, 2216, 2488, 2490, 2496, 2498, 2501, 2503, 2583, 2621 Oxidative stress and inflammation ........................ 1057, 2495 oxidative stress enzymes ................ 2404 oxidized phospholipids .................... 759 oxime .......................... 2014, 2016, 2049 oxycodone ........................................ 775 oxygen consumption ............ 2528, 2529 Oyster ............................................. 2430 ozone ... 26, 592, 604, 1244, 1293, 2286, 2287, 2326 P bodies .......................................... 2565 p16.......................................... 104, 2300 p21WAF1 ....................................... 1791 p27kip1 .......................................... 1070 p27kip-cyclin D1 ............................. 402 p38 mitogen activated protein kinase ............................................. 2064 P450 ....................................... 885, 1864 p53...................... 117, 1977, 2235, 2315 p53 haploinsufficient mice ............... 235 p53 mutation .................................. 1953 p53 stabilizer ............................ 794, 795 p62 autophage ................................ 1791 Pafuramidine .................................... 549 PAH ........................................ 355, 1213 PAH-contaminated soil .................. 2238 PAHs ................ 1074, 1373, 2396, 2524 pain ................................................... 512 PAK6 ................................................ 537 palmitate ......................................... 1664 pancreas ............................................ 380 pancreatic cancer .................... 225, 1663 pancreatitis ..................................... 2347 Paraoxon .............................. 2113, 2604 Paraoxonase ............... 1270, 1326, 2249 Paraoxonase 1 ................................ 2024 Paraquat ..................... 1295, 1348, 1349, 1665, 2265 Parkinson disease ................... 179, 1396 Parkinsonism .................................... 545 parkinsons disease ............................ 980 Parkinson’s disease ......... 168, 181, 182, 841, 843, 1348, 1394, 1779, 2123, 2124, 2134 PARP .................................... 1672, 2574 Particle ................................. 2333, 2491 particle characterization ....... 1233, 1801 particles ........................ 566, 1235, 1259 particokinetic model ....................... 1457 Particulate Matter ........................... 2659 particulate matter .... 591, 593, 671, 672, 1213, 1215, 1233, 1570, 2495 Particulate Matter (PM2.5) ........... 1170, 2323 Particulate Matters ......................... 1291 partition coefficient ........................ 1809 Pathological lesions ....................... 1933 Pathology ................................. 201, 536 Pathway analysis ...................... 125, 716 Pathway and network analysis ....... 1739 pathways .......................................... 130 Pax5................................................ 1123 Pb ........................................... 293, 1700 Pb toxicity ........................................ 293 PBDE ................................... 1667, 2253 PBDE 209 ...................................... 2604 PBPK............... 700, 707, 709, 721, 736, 889, 941, 2456, 2689, 2691, 2693 PBPK and Biological modeling ..... 2307 PBPK model.... 706, 708, 710, 711, 713, 718, 719, 737, 1239, 2690 616 SOT 2011 ANNUAL MEETING PBPK Modeling .......... 2, 699, 712, 720, 731, 1581, 2141, 2294, 2316, 2460 PBPK models ....................... 2457, 2688 PBPK/PD ................................. 723, 866 PC/PS Hemodialyzers .................... 1315 PC12 cells .......... 869, 1344, 1345, 1383 PCB ........ 1203, 1960, 2250, 2623, 2624 PCB 126 ............................... 1103, 1109 PCB126 .......................................... 1854 PCB136 .......................................... 1830 PCB3 metabolites............................. 335 PCBs ......... 621, 860, 1637, 2245, 2249, 2251, 2404, 2412, 2601, 2602, 2603 PCLis.............................................. 1004 PCR-RFLP ..................................... 1374 PDE4 Inhibitor ................................. 542 PDTC/Cu complex ........................... 300 penetration ........................................ 632 Penh................................................ 2299 peppermint oil ................................ 1107 Peptide Adducts ............................. 1679 peptide aggregation .......................... 734 peptide reactivity .............. 90, 905, 2545 Percellome ...................................... 1596 perfluorinated compounds ... 1221, 1636 Perfluorinated Phosphonic Acid .... 1625 Perfluoroalkyl acid ......................... 2240 perfluorochemicals ................. 657, 2240 Perfluorooctane sulfonate .............. 2243 Perfluorooctanoate ......................... 2557 perfluorophosphonic acid ............... 2239 Perinatal ............................................. 15 Perinatal Exposure ............... 1078, 2606 perinatal hypothyroidism ............... 1618 Peripheral Neuropathy ................... 2616 Permeability transition ................... 1087 peroxidation ................................... 2385 peroxisome proliferator-activated receptor gamma ...................... 957, 2661 Persistant Organic Chemicals, POP, Flame Retardant .................... 2248 persistent organic pollutants (POPs) ...... 212, 1200, 1202, 1593, 2244 Personal Care Products .................. 1551 personality ........................................ 628 pesticide .............. 181, 692, 1038, 1222, 1329, 1350, 1351, 1549, 1680, 1964, 2118, 2339, 2517 Pesticide exposure .......................... 1218 Pesticide Mixtures .......................... 1346 Pesticides ......... 105, 168, 242, 388, 531, 703, 704, 705, 864, 1202, 1250, 1328, 1779, 2110, 2111, 2112, 2115, 2116, 2120, 2244, 2387 PET Imaging Agent .......................... 812 petroleum ......................................... 108 petroleum diesel ............................. 2489 PFAA .............................................. 2247 PFAAs .............................................. 706 PFBA .............................................. 1242 PFHXA ........................................... 2272 PFHxS .................................. 2237, 2272 PFOA....... 205, 1089, 1242, 1609, 1620, 1622, 2271 PFOA/PFOS ................................... 2273 PFOS .................... 658, 659, 1242, 2271 P-glycoprotein ........................ 241, 2267 P-glycoprotein/ABCB1 .................. 2265 pH effects ....................................... 2155 pha .................................................. 1206 Phagocytic activation ....................... 251 Phagocytosis .......................... 263, 1272 Phamacokinetics ............................ 2263 Pharmaceutical ... 894, 2368, 2677, 2680 pharmaceutical agents .................... 2681 Pharmaceutical Ecotoxicology ....... 2400 pharmaceutical treatment ............... 2594 Pharmaceuticals .................. 1563, 1608, 1836, 2384 pharmacogenomics ........................ 1737 Pharmacokinetic ............. 517, 856, 1809 pharmacokinetic and pharmacodynamic modeling ............ 864 pharmacokinetic model .................. 2692 pharmacokinetics ........ 48, 51, 726, 732, 808, 920, 1266, 2056, 2100, 2257, 2258, 2262, 2274, 2281 pharmacological promiscuity ........... 853 Pharmacological similarity .............. 156 Pharmacology ...................... 1886, 2512 phase I ............................................ 1706 phase II ........................................... 1706 Phase II biotransformation ............. 1824 Phencyclidine ................................. 2596 Phenethyl Alcohol .......................... 1034 phenobarbital ........................ 2356, 2639 phenotype ............................... 363, 1718 Phosphatases .................................... 226 phosphatidylserine ......................... 1669 Phosphatidylserine exposure ............ 294 Phosphodiesterase ............................ 391 Phospholipidosis ........... 136, 436, 1426, 1452 Phospholipids ................................. 2195 phosphorylated kinase .................... 2159 Photocarcinogenesis ....................... 1785 photocarcinogenicity ........................ 796 Photo-clastogenicity ......................... 334 photoelectrocatalysis ............ 2408, 2409 photosynthesis ................................ 2385 Phototosensitization ....................... 2542 Phototoxicity ......... 157, 464, 638, 1012, 2078, 2541 phthalate ...... 67, 234, 1022, 1036, 1066, 1216, 1243, 1569, 2202, 2370 phthalates ............ 20, 1039, 1055, 1201, 1611, 2378 Phthalimide and phthalic acid ........ 2260 phycotoxins ................ 2225, 2226, 2402 Physical chemical ............................. 852 physicochemical characterization of particles ........................................ 847 physiochemical property ...... 1650, 2177 physiologically based kinetic modeling .......................................... 991 physiologically based pharmacokinetic modeling ...... 865, 938, 1582 Phytoestrogen ....................... 2197, 2198 phytoestrogens ........... 1053, 1062, 2362 phytopolyphenols ............................. 161 Pig-a ............................. 315, 1406, 1416 PIK3CA ............................................ 239 Pill .................................................. 1765 piperine .......................................... 2208 PK .................................................. 1929 PKC ................................................ 2208 placenta ................................ 1058, 1074 plant toxin ...................................... 2229 Plastics ............................................. 624 Platelet ............................................ 1884 Platelets ............................................ 778 Platycodon Grandiflorum .... 2207, 2209, 2211, 2213, 2217 PLD ................................................ 1299 pleura .................................... 2176, 2178 Pleural pressure ................................ 576 Plicopurpura pansa ......................... 2393 PLLA .............................................. 1322 Pluripotent Stem Cells ......... 1163, 1164 PM Exposure .................................. 2332 PM health effects ........................... 2494 pmk-1 ............................................. 2064 PML ................................................. 660 PMSF ............................................. 2101 Pneumotachometer, Correlation analysis ............................................. 576 POCIS ............................................ 2398 point of zero charge........................ 2177 Pol Eta .............................................. 120 Policy ............................................. 1527 pollutant ......................................... 1085 pollution ............................... 1543, 2396 pollution burden ............................... 472 polybrominated diphenyl ether ..... 1771, 2599 Polybrominated diphenyl ethers ... 1818, 2605 polybrominated diphenyl ethers (PBDEs) ............................... 1607, 2252 Polychlorinated biphenyls ..... 260, 1820, 2242 polychlorinated biphenyls (PCBs ) ... 1203, 1495, 2360, 2600, 2625 polychloroprene ............................. 1557 Polycyclic Aromatic Hydrocarbon ... 526 polycyclic aromatic hydrocarbons ........................ 1229, 2566 polycyclic aromatic hydrocarbons, Benzo(a)pyrene .............................. 1138 Polyethylene Glycol ......................... 781 poly-l-lactic acid ............................ 1322 polymorphism ............ 1361, 1362, 1778 polymorphisms ..................... 1255, 1372 polyphenols ............................ 995, 2231 Polysorbate 80 ...................... 1911, 1916 polystyrene nanosphere .................... 719 PON 1............................................. 1371 PON1.............................................. 1209 POP ................................................ 2241 POPs ..................................... 2200, 2305 population diversity ......................... 820 population variability ...... 501, 713, 819, 1984 port catheter system ....................... 1566 Positive Control ............................. 2654 postmenopausal women ................... 277 postnatal ......................................... 2663 postnatal body weight .................... 1025 Postnatal Development .................. 2190 post-translational modifications ....... 214 potassium bromate ......................... 1273 potentiation ...................................... 766 PPAR .... 234, 354, 358, 716, 1120, 1609 PPAR agonist ................................. 1437 PPAR alpha .......................... 2237, 2240 PPAR beta ........................................ 357 PPARa .............................................. 366 PPARa .............................................. 379 PPAR-alpha .......................... 1089, 2239 PPARb/d ................................... 355, 359 PPARg ...................................... 345, 352 PPD ................................................ 1863 Pralidoxime .................................... 2018 prasugrel ........................................... 777 pre and postnatal exposure ............. 1636 Precision-Cut Liver Slices ............ 1014, 1900, 2509 Precision-cut lung slices .................. 960 precision-cut tissue slices ............... 1766 Preclinical .................................... 3, 806 preclinical safety .................... 518, 1917 preclinical studies ........................... 1927 Preclinical Toxicology ........... 507, 1141 Prediabetes ..................................... 2201 prediction ....................................... 1410 Prediction Model .................... 717, 1598 Prediction Tools ............................. 1814 Predictive in vitro model ................ 2537 predictive methods ................... 148, 902 predictive modeling ....................... 1587 Predictive models ............................. 852 Predictive toxicology ............. 123, 2679 Pregnancy ........ 1067, 1625, 1985, 2186, 2197, 2506 pregnane X receptor ......................... 377 pregnane X receptor (PXR) ........... 1840 prenatal cigarette smoke ................ 2194 prenatal exposure ......... 611, 1208, 2607 Prenatal stress ....................... 1639, 1699
Keyword Index (Continued) preservatives .................................. 2570 pressure sensors ............................. 1930 preterm birth ..... 1052, 1057, 1076, 2563 Prevalidation .................................. 2551 Preventive Medicine ...................... 1225 Primary B Cells .............................. 1137 Primary cell cultures ...................... 1332 Primary dendritic cells ..................... 967 primary hepatocyte culture .. 1656, 2511 primary hepatocytes ............. 1861, 2523 Primate ................................. 1914, 1924 primates .............................................. 26 Primrose ......................................... 2442 prion ................................. 841, 844, 845 prion disease ..................................... 173 problem formulation ...................... 2507 Procoagulant activation .................. 1884 Product Design ............................... 2696 product development ...................... 2564 Profenofos ...................................... 2117 professional development .............. 2484 Program development .................... 1876 prohapten ...................................... 86, 88 Prohormone convertase .................. 2089 proinflammatory ............................ 1748 proinflammatory mediators .............. 260 Prolactin ......................................... 2372 proliferation .............................. 639, 951 promoter ........................................... 397 Pro-oxidant actions ........................ 1307 propanol ......................................... 2294 propentofylline ................................. 506 propiconazole ......................... 951, 2109 propyl acetate ................................. 2294 propyl paraben ............................... 1823 Prostate ........................................... 1624 Prostate cancer ..................... 1043, 2091 prostate development ..................... 1626 proteasome ..................................... 2490 Protein .................. 127, 842, 1730, 2453 protein adducts ..................... 1262, 1433 protein aerosol .................................. 589 Protein binding ............................... 2348 protein corona ................................ 1488 protein denaturation ....................... 1733 protein hydrolysates ........................... 89 Protein Kinase .................................... 34 protein kinase C ............................. 2131 Protein Ligand Binding .................... 408 Protein Microarray ......................... 1442 protein safety .... 1728, 1731, 1732, 1733 Protein-protein interaction network ............................................ 134 proteins ........................................... 1729 proteolytic enzymes ........................... 96 proteome ........................................ 2136 Proteomics ....................... 129, 213, 970, 1084, 1283, 1286, 1446, 1450, 1745, 2017, 2159, 2223, 2387 proteomics ...................................... 1284 Pseudoallergic & anaphylactoid reactions ............................................... 7 pseudoallergy ................................. 1500 Pseudoestrogens ............................. 2256 Pseudomonas aeruginosa ............... 2337 Psidium guajava ............................. 2218 PTEN................................................ 954 PTH ................................................ 2376 pubertal assay ................................. 2356 public health ..................... 23, 830, 2153 publication ...................................... 2482 pulmonary ..... 566, 594, 811, 895, 2167, 2190 pulmonary disease and toxicology ... 590 pulmonary exposure ......................... 192 pulmonary fibrisos ........................... 540 Pulmonary Function ............. 1199, 1800 pulmonary health ........................... 2057 pulmonary inflammation . 186, 541, 603, 1458, 2327 pulmonary injury ............................ 1190 pulmonary injury biomarkers ......... 2477 Pulmonary Toxicity ... 1178, 1473, 1496, 1798 Purinergic Signaling ....................... 1477 PXR .................................................. 385 Pyrethroid ........... 723, 1341, 2104, 2119 pyrethroid pesticide ........................ 1476 pyrethroid pesticides ... 873, 1340, 1342, 2093 pyrethroids ...... 1343, 1344, 1345, 1857, 2262 Pyridazine ...................................... 2283 Pyriproxyfen .................................... 348 Pyrosequencing ................................ 101 pyrrocidine ..................................... 2428 Q-dots ................................... 1197, 2184 qHTS ........................................ 493, 981 qHTS data ........................................ 482 qPCR .............................................. 1368 QSAR ...... 136, 139, 146, 157, 159, 465, 468, 483, 487, 492, 494, 496, 499, 721, 723, 861, 1812, 2464, 2538 QSAR modeling ..................... 484, 1816 QSAR/QSPR .................................... 633 qsars ................................................. 849 QT prolongation ............................... 195 Quality assurance ........................... 2439 quantitation .................................... 1926 Quantitative behavioural assessment ........................................ 780 quantitative high throughput screening ........................................ 2501 Quantitative Structure Activity Relationship ................................... 1811 Quantitative structure-activity relationships QSAR ............... 722, 2298 quantitative trait loci ........................ 823 Quantum dot ................................... 1193 quantum dot nanoparticles ............ 1175, 2154, 2155 Quantum Dots ........... 1197, 1465, 2168, 2183, 2184 quinolone ........................................ 1076 quinone ........................................... 1292 Quinones ........................................ 1433 QWBA (quantitative whole body authoradiography) .......................... 2257 R, R-monatin .................................. 2421 R2C .................................................. 999 rabbit minipig ................................. 1927 Rabbits ........................................... 1630 Ractopamine .................................. 2431 Rad23 ............................................... 306 radiation ............. 324, 1248, 2010, 2577 radio frequency radiation ............... 2627 Radionuclide Decorporation .......... 2291 rainbow trout .................................. 1588 Raman ............................................ 1260 raoxifene ........................................ 2634 RAP80 ............................................ 2636 Ras................................ 951, 1781, 2637 ras oncogene ................................... 1783 rasH2 ................................................ 508 rasH2 mouse ..................................... 521 RasH2 Transgenic Mice ................. 2654 rat .................... 246, 512, 555, 738, 774, 1423, 2281 rat and fetal alcohol syndrome ....... 2613 rat hepatocytes ..................... 1107, 2242 Rat Model ....................................... 1819 Rat primary Hepatocytes ................ 1595 rat spleen .......................................... 547 Rat Testicular cell line ...................... 999 rat urinary bladder ............................ 525 Rat, Rabbit ....................................... 648 rats .......................................... 649, 1611 RD50 .............................................. 2296 RDX ................................................. 736 REACH .................. 298, 470, 499, 1516 reaction chemistry .......................... 1558 reactive intermediate ........................ 319 reactive metabolite ......................... 1832 Reactive Metabolites ............... 154, 424, 425, 888 Reactive Orange 16 .......................... 336 reactive oxygen .............................. 1859 Reactive Oxygen Species ........ 191, 579, 591, 1000, 1052, 1273, 1491, 1655, 1838, 2175 reactive oxygen species (ROS) ...... 2560 read-across ....................................... 298 Realgar ................................. 2004, 2006 ReCell .............................................. 892 receptor-mediated............................. 475 receptors ......... 346, 350, 367, 384, 1892 reconstituted model .......................... 975 reconstructed human skin ................ 341 recruiting ........................................ 2486 Red algae ........................................ 1571 red blood cells ................................ 1411 Redistribution ® Technology ............. 398 Redox ................................... 1299, 1349 Redox state ....................................... 877 reduced intrauterine growth ............. 614 Reendothelialization ...................... 1320 reference concentrations .................. 502 Reference database ............................... 4 reference dose ...................... 1542, 1940 Reference Ranges ............................. 636 Regeneration .................................... 765 regulation ................... 1727, 2376, 2695 regulation/policy .............................. 996 Regulatory ...................................... 2508 regulatory acceptance ..................... 1309 Regulatory Developmental toxicity ........................................... 1623 regulatory evolution ....................... 1775 Regulatory Requirements ............... 2375 regulatory T cells ......... 689, 1131, 1139 Regulatory Toxicology ........ 1527, 1563, 1793 Renal .............................................. 1438 renal absorption .............................. 2283 renal biomarkers ............................... 754 renal drug transporter ....................... 762 renal failure .................................... 1561 renal fibrosis ..................................... 759 Renal Injury ..................................... 748 Renal Proximal Tubule Cells ... 749, 751 renal toxicity .................................... 745 Renal Toxicology ........................... 1274 Repeat Dose Studies ...................... 1524 Repin ................................................ 545 reporter assays ................................ 2532 reproducibility ................................ 1562 reproduction .... 1024, 1038, 1074, 2384, 2395, 2546 Reproduction and Development ... 1060, 2202 Reproductive .... 1029, 1030, 1050, 1059 reproductive organ ......................... 1046 Reproductive outcome ................... 1208 Reproductive Performance ............. 1028 Reproductive Toxiciology .............. 1147 reproductive toxicity .................. 16, 717 reproductive toxicology ........... 67, 1051 reprogramming ............................... 2453 reprotoxicity ................................... 1231 resazurin ......................................... 1904 research and job-seeking skills ...... 2483 research experience for undergraduates.......................... 1873 residues .......................................... 2119 resorufin ......................................... 1904 Respiratory ...... 1196, 1914, 1920, 1921, 2476 respiratory allergen .......................... 907 Respiratory allergy ..................... 84, 903 respiratory effects ............................. 611 Respiratory epithelium ......... 2329, 2480 respiratory sensitization ....... 90, 97, 905 Respiratory thoracic impedance ....... 576 respiratory toxicity .... 1555, 2029, 2041, 2474, 2478 respiratory tract ... 595, 889, 2290, 2475, 2478, 2479 Respiratory, lung ............................ 2474 Restenosis ...................................... 1320 Resume preparation ....................... 2485 resveratrol .......... 741, 1670, 2227, 2321 Retailers ......................................... 2115 retinoic acid ................ 1506, 2088, 2369 retinol ................................................. 74 Retinopathy of prematurity ............ 2587 retrotransposons ................................. 99 r-H2AX ............................................ 118 Rhabdomyosarcoma and canine cancers .................................. 955 rhinitis ................................................ 97 Rhinovirus ...................................... 1289 Ribbon worm ................................. 2430 Ribosomal RNA Cleavage ............. 1662 Ribosome ..................................... 34, 38 Ribosome inactivating protein ........... 39 ribosome-inactivating protein ........ 2414 Ribosome-inactivating stress ........... 370 Ribosomes .......................................... 39 ribotoxic stress ................. 35, 36, 37, 39 ricin .................. 2017, 2223, 2432, 2433 right whale ..................................... 2405 Rip1 .................................................. 308 risk..................... 367, 1263, 1535, 1936, 2694, 2699 Risk and Safety Assessment ........... 2630 Risk Assessment.................. 2, 8, 11, 13, 47, 48, 49, 52, 154, 332, 471, 476, 480, 483, 485, 489, 500, 501, 502, 586, 701, 703, 704, 705, 712, 720, 830, 848, 851, 862, 904, 916, 921, 925, 931, 1251, 1346, 1424, 1529, 1530, 1531, 1532, 1534, 1536, 1537, 1543, 1545, 1554, 1568, 1569, 1576, 1581, 1701, 1715, 1717, 1728, 1732, 1733, 1767, 1797, 1799, 1805, 1813, 1877, 1933, 1934, 1937, 1939, 1955, 1963, 1964, 1965, 2106, 2286, 2289, 2296, 2307, 2308, 2309, 2438, 2456, 2457, 2459, 2460, 2462, 2538, 2573, 2682, 2688, 2689, 2690, 2691, 2692 Risk Assessment Methods.............. 1938 Risk Characterization ..................... 1680 risk communication .......................... 933 risk exposure .................................. 2431 risk management .................. 1517, 2153 risk versus benefits ......................... 1796 rituximab .......................................... 661 Rivers ............................................. 2403 RNAi ...................................... 522, 1861 rodent chow diet ............................. 1062 Rodent Study .................................. 1909 rodents .................................... 519, 2614 ROS .... 220, 415, 753, 1668, 2003, 2070 rotenone .......................................... 1900 RT-PCR arrays ............................... 1583 RUNX2 .......................................... 2217 rural population .............................. 1209 Ryanodine ...................................... 2623 Ryanodine receptor .............. 2246, 2624 S-(1, 2-Dichlorovinyl)-L-cysteine sulfoxide ........................................... 755 S100A4/7 ....................................... 2649 S1P ................................................. 1892 safer alternatives .............. 911, 912, 913 Safety ............ 10, 558, 811, 1765, 2428, 2437, 2439 Safety Assessment ... 651, 742, 782, 783, 790, 808, 1060, 1317, 1318, 1319, 1323, 1541, 1561, 1892, 1896, 1911, 1916, 1925, 2440, 2441 SOT 2011 ANNUAL MEETING 617 KEY WORD INDEX
Page 1 and 2:
The Toxicologist Supplement to Toxi
Page 3 and 4:
The Toxicologist Supplement to Toxi
Page 5 and 6:
1 BIODEGRADABLE MATERIALS FOR TISSU
Page 7 and 8:
that genetic toxicology data are ge
Page 9 and 10:
well-orchestrated lung inflammation
Page 11 and 12:
scribed in the literature. We have
Page 13 and 14:
years ago). We will illustrate how
Page 15 and 16:
involved in the biodegradation proc
Page 17 and 18:
stem cells but rather a treatment i
Page 19 and 20:
additional compound showed agreemen
Page 21 and 22:
82 COMPARISON OF 3H-THYMIDINE INCOR
Page 23 and 24:
irritants. While in practice these
Page 25 and 26:
alleles are especially vulnerable t
Page 27 and 28:
109 CD4+ T CELL INTRINSIC TNF RECEP
Page 29 and 30:
118 TO STUDY THE SIGNAL TRANSDUCTIO
Page 31 and 32:
PAHs, such as dioxins, are prevalen
Page 33 and 34:
containing substituents and/or hydr
Page 35 and 36:
146 COMPUTATIONAL MODELING FOR QT P
Page 37 and 38:
suggest that the combination of too
Page 39 and 40:
164 TRANSLOCATOR PROTEIN (18 KDA) (
Page 41 and 42:
function as a metal binding protein
Page 43 and 44:
laboratory has demonstrated that NR
Page 45 and 46:
known. The aim of this study was to
Page 47 and 48:
from 5 to 28 days in duration) in e
Page 49 and 50:
positive cells, caspase-3 activatio
Page 51 and 52:
creased level in the 46 kDa preproe
Page 53 and 54:
invasiveness at concentrations repr
Page 55 and 56:
thracene (DMBA,50 μg in acetone, a
Page 57 and 58:
247 CO-CARCINOGENESIS OF N, N- DIET
Page 59 and 60:
sponds to the endosomal dsRNA that
Page 61 and 62:
ODD in both WT (maximum 177% of con
Page 63 and 64:
Lastly, using p53siRNA cells, p53 w
Page 65 and 66:
its receptor Mpl to exert its funct
Page 67 and 68:
294 LOW LEVEL OF LEAD CAN INDUCE PH
Page 69 and 70:
lunar surface presented potential h
Page 71 and 72:
lar about cellular export mechanism
Page 73 and 74:
DNA in the kidney medulla, grandula
Page 75 and 76:
5.00 and 7.50 mg/kg/day by oral gav
Page 77 and 78:
events and carcinogenesis. Here we
Page 79 and 80:
tinization of cells of the hair fol
Page 81 and 82:
358 CHARACTERIZATION OF GENOME-WIDE
Page 83 and 84:
RNAi were also performed to identif
Page 85 and 86:
376 A FUNCTIONAL CROSSTALK BETWEEN
Page 87 and 88:
UGT1A gene induction, while this re
Page 89 and 90:
tivity, specifically peroxisome pro
Page 91 and 92:
and cytotoxic effects; however, its
Page 93 and 94:
histone deacetylase that is necessa
Page 95 and 96:
ment. Paradoxically, buthionine sul
Page 97 and 98:
drug leflunomide and its major (A77
Page 99 and 100:
442 GENE EXPRESSION AND MORPHOLOGIC
Page 101 and 102:
451 INHIBITION OF THE MITOCHONDRIAL
Page 103 and 104:
460 SULFORAPHANE PREVENTS ACETAMINO
Page 105 and 106:
drophilic/lipophilic balance. Other
Page 107 and 108:
pharmacokinetic and toxicological p
Page 109 and 110:
489 USE OF ‘OMICS DATA TO IMPROVE
Page 111 and 112:
498 APPLICATION OF AGE-SPECIFIC ADJ
Page 113 and 114:
507 A DOSE VOLUME TOLERABILITY STUD
Page 115 and 116:
involved the use of an acute inflam
Page 117 and 118:
sorption in the gastrointestinal (G
Page 119 and 120:
(ABC) transporters actively transpo
Page 121 and 122:
545 BEHAVIORAL EFFECTS OF REPIN IN
Page 123 and 124:
a blood pressure phenotype that res
Page 125 and 126:
and inhalation exposure system that
Page 127 and 128:
and lethality associated with these
Page 129 and 130:
position, on vascular reactivity an
Page 131 and 132:
therefore more accurate and reprodu
Page 133 and 134:
commercial chrysotile product that
Page 135 and 136:
elative to their controls. ST-depre
Page 137 and 138:
ats. The majority of the studies fo
Page 139 and 140:
in the China Jintan Child Cohort St
Page 141 and 142:
corneum thickness, cellular epiderm
Page 143 and 144:
645 EVALUATION OF THE IN VITRO EPIS
Page 145 and 146:
654 TCDD ADSORBED ONTO NATURAL AND
Page 147 and 148:
tion revealed no test article-relat
Page 149 and 150:
671 INFLAMMATION AND TISSUE DAMAGE
Page 151 and 152:
model, ethanol was found to inhibit
Page 153 and 154:
689 ENHANCED SUPPRESSIVE FUNCTION O
Page 155 and 156:
NAC + LPS yielded different levels
Page 157 and 158:
707 LIFE-STAGE PBPK MODELS FOR MULT
Page 159 and 160:
downstream of the apical endpoint o
Page 161 and 162:
726 UPDATED ALUMINUM PHARMACOKINETI
Page 163 and 164:
global parameter sensitivity analys
Page 165 and 166:
and renal inflammation induced by 2
Page 167 and 168:
754 PLASMA, URINE, AND TISSUE CONCE
Page 169 and 170:
cently characterized transporter OA
Page 171 and 172:
exposure system was developed from
Page 173 and 174:
lood cell mass and decrease in urin
Page 175 and 176:
practical alternatives to MC in non
Page 177 and 178:
imals dosed with 167 mg/kg THU alon
Page 179 and 180:
and organ weights, clinical signs a
Page 181 and 182:
yet is induced in most bladder and
Page 183 and 184:
830 RISK ASSESSMENT OF THE SPILL: C
Page 185 and 186:
knowledgebase creation. Results are
Page 187 and 188:
852 UNDERSTANDING STRUCTURAL AND PH
Page 189 and 190:
for integrating epidemiology and an
Page 191 and 192:
motor activity, including age of th
Page 193 and 194:
y partial purification of urine (fr
Page 195 and 196:
pacity for self-renewal and may dif
Page 197 and 198:
sue. The depth of our analysis led
Page 199 and 200:
910 IMPLEMENTING CALIFORNIA’S GRE
Page 201 and 202:
concentrations in six tissues and b
Page 203 and 204:
934 THE FDA’S LIVER TOXICITY KNOW
Page 205 and 206:
943 GENOME-WIDE DNA METHYLATION DIF
Page 207 and 208:
membrane localization and subsequen
Page 209 and 210:
trols, respectively. Subtoxic and t
Page 211 and 212:
survival using both smoking regimes
Page 213 and 214:
as non-, weak, moderate, or strong
Page 215 and 216:
988 NNK-INDUCED CYTOKINE ALTERATION
Page 217 and 218:
group (one-way ANOVA, p90 % viabili
Page 219 and 220:
ered as an organ involved in xenobi
Page 221 and 222:
Transport of CPZ across the Caco-2
Page 223 and 224:
estrous cycle and sexual behavior d
Page 225 and 226:
mRNA expression levels. Collectivel
Page 227 and 228:
1043 THE EFFECTS OF ENDOCRINE DISRU
Page 229 and 230:
1052 MONO-2-ETHYLHEXYL PHTHALATE IN
Page 231 and 232:
Results: MC was variable within and
Page 233 and 234:
UtSMCs. Phosphorylation of FoxO1 wa
Page 235 and 236:
nonpregnant and pregnant diabetic m
Page 237 and 238:
1089 PFOA-INDUCED LIVER EFFECTS IN
Page 239 and 240:
events in the liver. AZD9056 was ev
Page 241 and 242:
The peppermint oil caused a concent
Page 243 and 244:
OA did not affect food consumption.
Page 245 and 246:
1126 PERSISTENT DEVELOPMENTAL ARYLH
Page 247 and 248:
1135 BACH2 BINDING TO Prdm1 AS A ME
Page 249 and 250:
The purpose of this project was to
Page 251 and 252:
one marrow. Since Chk1 is an attrac
Page 253 and 254:
1163 THE MRNA AND MIRNA PROFILE OF
Page 255 and 256:
have now compared the IC50 values b
Page 257 and 258:
1181 ELUCIDATION OF FACTORS DETERMI
Page 259 and 260:
enced by pre-exposure to cigarette
Page 261 and 262:
if abnormal PF was associated with
Page 263 and 264:
weight (P=0.016) and small for gest
Page 265 and 266:
portant cause of death, compared to
Page 267 and 268:
posure groups. However, the differe
Page 269 and 270:
Naphthalene is routinely analyzed i
Page 271 and 272:
1245 SEASONAL CHARACTERIZATION OF H
Page 273 and 274:
1255 URINARY T, T MUCONIC ACID LEVE
Page 275 and 276:
modating a reliable data evaluation
Page 277 and 278:
enzoquinone generate ROS and arylat
Page 279 and 280:
teins (e.g. C3, 4, and 5, APOB, VDB
Page 281 and 282:
1293 TRANSFORMING GROWTH FACTOR BET
Page 283 and 284:
mation was decreased to the same le
Page 285 and 286:
1312 EVALUATION OF THE SENSITIVITY
Page 287 and 288:
luted OFR and CRL. Culture media ex
Page 289 and 290:
urinary TCPy levels, blood and brai
Page 291 and 292:
activity. The dose-response curves
Page 293 and 294:
mice, each with 4 dose groups. One
Page 295 and 296:
exposure to both ATR and DACT has a
Page 297 and 298:
third tetratricopeptide repeats (TP
Page 299 and 300:
7d. 28d after TMT injury there was
Page 301 and 302:
subunits. Each cell type was treate
Page 303 and 304:
1394 COMPARATIVE EFFECTS OF METHYLM
Page 305 and 306:
1403 GENOTOXICITY AND PRE-NEOPLASTI
Page 307 and 308:
vated only in high-dose-treated ani
Page 309 and 310:
1421 DOSE-RESPONSE OF NAPHTHALENE-I
Page 311 and 312:
cisplatin; 1.2-, 1.9- and 2.9-fold
Page 313 and 314:
Day 11 and started to recover on Da
Page 315 and 316:
1448 DEVELOPMENT OF A METHOD FOR QU
Page 317 and 318:
1457 GLOBAL GENE PROFILING REVEALS
Page 319 and 320:
cluding mouse and human macrophage,
Page 321 and 322:
model of lung inflammation and host
Page 323 and 324:
1484 NANOTOXICOLOGY AND NANOHEALTH
Page 325 and 326:
throughput in vitro approach was us
Page 327 and 328:
1502 IMMUNOLOGICAL ASPECTS OF AN AN
Page 329 and 330:
(CIA) and the Streptococcal cell wa
Page 331 and 332:
sitizers were 100% concordant among
Page 333 and 334:
1530 MINIMAL RISK LEVELS FOR STYREN
Page 335 and 336:
ical groups in the field of regulat
Page 337 and 338:
vitro with this potentially insect-
Page 339 and 340:
their performance on toxicological
Page 341 and 342:
need for a better understanding of
Page 343 and 344:
1577 AN IN VITRO MODEL SYSTEM FOR A
Page 345 and 346:
gene expression post-transcriptiona
Page 347 and 348:
1595 GENE EXPRESSION PROFILE OF RAT
Page 349 and 350:
to confirm a hepatotoxic property o
Page 351 and 352:
1613 AN INVESTIGATION OF THE CLEARA
Page 353 and 354:
its nuclear translocation was reduc
Page 355 and 356:
were collected from TK animals at d
Page 357 and 358:
egulated targets were selected for
Page 359 and 360:
U/L after tetracycline. Minocycline
Page 361 and 362:
peri-pubertal FasL-/- mice show a d
Page 363 and 364:
showed similar levels of apoptosis
Page 365 and 366:
1676 TWO BIOMARKERS FOR EVALUATION
Page 367 and 368:
motifs selected. This system was ap
Page 369 and 370:
1693 VOC SERUM LEVELS IN THE GENERA
Page 371 and 372:
1702 DOES THE CLOCK MAKE THE POISON
Page 373 and 374:
those with high nickel content are
Page 375 and 376:
isk assessment. However, unique cha
Page 377 and 378:
model of APAP metabolism and glutat
Page 379 and 380:
logically & morphologically similar
Page 381 and 382:
posure, blood chemistry was analyze
Page 383 and 384:
elated to oxidative stress by measu
Page 385 and 386:
ostasis), but work is needed to tra
Page 387 and 388:
tokine products during carcinogenes
Page 389 and 390:
ways as chemical stressors and, the
Page 391 and 392:
toxicity of nanomaterials relates s
Page 393 and 394:
1815 MEASURING COMPOUND SELECTIVITY
Page 395 and 396:
1825 EFFECTS OF METABOLISM BY INTES
Page 397 and 398:
cyanoacetic acid increased 2-3 fold
Page 399 and 400:
1845 IS THE PROMISCUITY OF THE ARYL
Page 401 and 402:
crorarray analysis. RT-PCR results
Page 403 and 404:
are a family of phase-II biotransfo
Page 405 and 406:
ous labs. As a result of positive s
Page 407 and 408:
down the doses may produce more tox
Page 409 and 410:
spectively. Below 100 mg/l of gemfi
Page 411 and 412:
1900 GENERATION OF PRECISION CUT LI
Page 413 and 414:
iomarkers or observation of lesions
Page 415 and 416:
creased reticulocytes and lymphocyt
Page 417 and 418:
statistically significant interacti
Page 419 and 420:
monize sample preparation and analy
Page 421 and 422:
NPC and sinonasal cancer in neighbo
Page 423 and 424:
showed incidences of lung and nasal
Page 425 and 426:
utylbenzenes, exhibited most simila
Page 427 and 428:
1975 DIFFERENTIAL MODULATION OF CYP
Page 429 and 430:
organic As to MMA(V) and a lower ca
Page 431 and 432:
ole in invasion and metastasis of c
Page 433 and 434:
3T3-L1 cells to low-levels of arsen
Page 435 and 436:
2011 IDENTIFICATION OF A NOVEL VX M
Page 437 and 438:
This work was supported by Cooperat
Page 439 and 440:
2029 EFFICACY OF ENDOTRACHEAL ADMIN
Page 441 and 442:
Diazepam injections and its combina
Page 443 and 444:
2047 ESTERASE ACTIVITIES AND HEMOST
Page 445 and 446:
nanoparticle-induced toxicity progr
Page 447 and 448:
house, were iv infused into rats ov
Page 449 and 450:
een explored. This study investigat
Page 451 and 452:
croscopic analysis revealed that on
Page 453 and 454:
egg yolk collected from turtles inh
Page 455 and 456:
consistency of results in both expe
Page 457 and 458:
2111 CYTOCHROME P450 3A5 GENOTYPE I
Page 459 and 460:
esidues of organophosphates or thei
Page 461 and 462:
manganism. Recent work from our lab
Page 463 and 464:
Aβ1-40 in CSF and hippocampus in P
Page 465 and 466:
2147 CATALASE MANIPULATIONS MODIFY
Page 467 and 468:
ation based on real-world exposure
Page 469 and 470:
NPs. Aggregation of citrate-stabili
Page 471 and 472:
2175 THE ROLE OF SURFACE CHEMISTRY
Page 473 and 474:
seen rapid uptake in biological ima
Page 475 and 476:
effect on uterine weight or vaginal
Page 477 and 478:
dicating widespread exposure. While
Page 479 and 480:
components into the liver parenchym
Page 481 and 482:
2223 ISOLATION AND DETECTION OF RIC
Page 483 and 484:
stored (-20 celsius degree). The co
Page 485 and 486:
2241 DDA, A BIOMARKER FOR ENVIRONME
Page 487 and 488:
2249 INTERACTION BETWEEN DIETARY SE
Page 489 and 490:
2258 PHARMACOKINETICS, EXCRETION BA
Page 491 and 492:
2267 SENSITIVE AND SPECIFIC FLUORES
Page 493 and 494:
2276 METABOLISM AND DISPOSITION OF
Page 495 and 496:
ment of hypertension in companion a
Page 497 and 498:
for the propyl series can be used f
Page 499 and 500:
2304 IN VITRO EXPOSURE AND EVALUATI
Page 501 and 502:
2313 THE SYNERGISTIC EFFECT OF SODI
Page 503 and 504:
genes that play a crucial role in M
Page 505 and 506:
2330 THE ROLE OF TRANSFORMING GROWT
Page 507 and 508:
ined following up to 96 h continuou
Page 509 and 510:
effect doses obtained with the rat
Page 511 and 512:
diated transcriptional response of
Page 513 and 514:
docrine disruptor activities of EDC
Page 515 and 516:
individuals. Week 6 results were qu
Page 517 and 518:
functionality of photosystem II and
Page 519 and 520:
wild mice (Mus musculus) from areas
Page 521 and 522:
2406 TOXICITY AND BIOACCUMULATION O
Page 523 and 524:
Isocitric acid is the acid in the h
Page 525 and 526:
2425 EFFECTS OF FUMONISINS IN ETHAN
Page 527 and 528:
centration(μg/g) were: 5.1-95.3; 2
Page 529 and 530:
2445 AUTOPHAGY IN DEVELOPMENT: A LI
Page 531 and 532:
sures to inhaled Mn in dust. Nevert
Page 533 and 534:
2466 CRITICAL EVALUATION OF ANIMAL
Page 535 and 536:
elationships predict that resting r
Page 537 and 538:
2489 COMPARATIVE TOXICITY OF BIODIE
Page 539 and 540:
2497 TRANSCRIPTIONAL REGULATION OF
Page 541 and 542:
2506 TOXICOLOGICAL CONSIDERATIONS O
Page 543 and 544:
launched with the aim of developing
Page 545 and 546:
forms mRNA expression levels were a
Page 547 and 548:
2534 CUTANEOUS WOUND HEALING IN THE
Page 549 and 550:
wells (0, 1, 5, 10, 25, 50, 100, an
Page 551 and 552:
2553 AN ORGANOTYPIC MICROLIVER PLAT
Page 553 and 554:
serum-free media. At 24 hrs, the gr
Page 555 and 556:
2572 INCREASED ARSENIC BIOACCESSIBI
Page 557 and 558:
nology to develop improved methods.
Page 559 and 560:
tuna, swordfish, or mako shark (3.5
Page 561 and 562:
nificantly reduce circulating thyro
Page 563 and 564:
grouped into 9 observation periods
Page 565 and 566:
histopathological or biochemical ev
Page 567 and 568:
exhibited a hyperactive phenotype,
Page 569 and 570: the search of effective drugs for e
Page 571 and 572: 2644 COVALENT BINDING OF 14 C 2-MET
Page 573 and 574: aries targeting all transcription f
Page 575 and 576: (p 9 weeks) and CSC phenotype acqui
Page 577 and 578: 2673 IMMUNE-MEDIATED VASCULAR INJUR
Page 579 and 580: for risk identification and charact
Page 581 and 582: to control toxicant delivery in tob
Page 583 and 584: Author Index (Continued) The numera
Page 611 and 612: Keyword Index (Continued) Arsenite
Page 613 and 614: Keyword Index (Continued) Covalent
Page 615 and 616: Keyword Index (Continued) flow cyto
Page 617 and 618: Keyword Index (Continued) innate im
Page 619: Keyword Index (Continued) nanoparti
Page 623 and 624: Keyword Index (Continued) Thrombocy
Page 625 and 626: Toxicological Sciences The Official
show all

The Toxicologist - Society of Toxicology

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?